Background: Despite recent advances, infection remains the most common etiology of arthroplasty failure. Recent work
of arthroplasty failure 2 . PJIs are devastating, resulting in reoperations, prolonged antibiotic therapy, and extended disability and rehabilitation, with up to 7% of patients dying between the first and second stages of exchange arthroplasty 3, 4 . Medical costs are enormous, averaging $145,000 per patient, resulting in a proposed projected annual U.S. health-care burden of $8.6 billion by 2030 5, 6 . While effort has been focused on perioperative antimicrobial therapies and modification of health-care systems protocols, host factors governing susceptibility to PJI have been understudied. Although smoking, obesity, and diabetes mellitus (among others) are known risk factors, mechanistic links have been difficult to ascribe, and efforts at modifying these factors have been challenging [7] [8] [9] [10] [11] . 25-hydroxyvitamin D 3 (25D 3 ) holds promise as a risk modifier for 3 important reasons. First, epidemiologic data demonstrate that >65% of patients undergoing arthroplasty have an insufficient or low level of total 25-hydroxyvitamin D (25D; accounts for both 25D 2 and 25D 3 in the serum) 12 . Second, recent epidemiologic work has suggested that vitamin-D deficiency is directly correlated with the frequency of PJI 13 . This coincides with literature highlighting the importance of the prohormone 25D as a locally active immune modulator for antigen-activated inflammatory cells. This is mediated through the intracellular enzymatic conversion of available 25D to 1,25-dihydroxyvitamin D (1,25D) via the CYP27B1-hydroxylase, which is coupled to the expression of the vitamin-D receptor. The vitamin-D receptor regulates the expression of genes critical to both the innate and adaptive immune responses in humans [14] [15] [16] [17] [18] [19] [20] . Finally, 25D levels can be returned to normal with ease, rapidity, efficiency, and low cost using an available, U.S. Food and Drug Administration (FDA)-approved, orally administered 25D 3 product 21 . Taken together, 25D deficiency is prevalent in the population receiving total joint arthroplasty, appears to be correlated with PJI clinically and linked to the function of the innate immune response mechanistically, and can be easily improved, highlighting its promise as a modifiable risk factor.
The objective of the current study was to examine whether the immune system is suppressed in the 25D-deficient state, increasing the severity of a PJI. We aimed to test 2 primary hypotheses. First, does 25D 3 deficiency lead to an increased bacterial burden and decreased inflammatory response in vivo in an established mouse model of PJI? Second, if that is the case, does "rescue" with preoperative 25D 3 supplementation reverse this effect? If successful, such findings could pave the way for establishing a low serum 25D level as an easily modifiable host factor in humans to reduce the risk of PJI.
Materials and Methods
A ll animals were handled according to good animal practice as defined in the federal regulations set forth in the Animal Welfare Act, the 1996 Guide for the Care and Use of Laboratory Animals, and the Public Health Service Policy for the Humane Care and Use of Laboratory Animals as well as the policies and procedures of the University of California, Los Angeles (UCLA).
All animal experiments were approved by the UCLA chancellor's Animal Research Committee.
Staphylococcus aureus Bioluminescent Strain
Staphylococcus aureus Xen36 (PerkinElmer) is a bioluminescent derivative of the S. aureus ATCC 49525 (Wright) strain, derived from a patient with S. aureus bacteremia. Xen36 has a grampositive optimized luxABCDE operon stably integrated into a large native plasmid 22 . This strain emits a blue-green light with a maximal emission wavelength of approximately 490 nm from live, actively metabolizing bacteria and was previously shown to be optimal for use because of the strength and consistency of its signal 6 .
Preparation of S. aureus for Inoculation
Xen36 possesses a kanamycin-resistance selection marker, enabling isolation from contaminating background strains during culture. Thus, 200 mg/mL of kanamycin (Sigma-Aldrich) was added to all culture samples. Xen 36 was streaked onto tryptic soy agar plates (tryptic soy broth [TSB] plus 1.5% Bacto agar; BD Biosciences) and grown at 37°C overnight. Single colonies were cultured in TSB and grown overnight at 37°C in a shaking incubator (240 rpm) (MaxQ 4450; ThermoFisher Scientific). Midlogarithmic-phase bacteria were obtained after a 2-hour subculture of a 1:50 dilution of the overnight culture. Cells were pelleted, resuspended, and washed 3 times in phosphate buffered saline (PBS) solution. Bacterial concentrations were estimated by measuring the absorbance at 600 nm (BioMate 3; ThermoFisher Scientific). Colony forming units (CFUs) were verified after overnight culture of plates.
Mice
We used 4-week-old male lys-EGFP mice, a genetically engineered mouse line on a C57BL/6 background possessing green-fluorescent myeloid cells (mostly neutrophils) as a consequence of "knock-in" of enhanced green fluorescent protein (EGFP) into the lysozyme M gene 23, 24 . Animals were kept 3 mice per cage and fed either a standard diet (4, 200 IU vitamin D 3 per kg of feed) or a vitamin D 3 -deficient diet (0 IU vitamin D 3 added; Research Diets) with access to bottled water. Veterinary staff carried out daily assessments.
Vitamin-D Protocol
The mice were randomized to receive either a vitamin D 3 -sufficient (n = 20) or vitamin D 3 -deficient (n = 40) diet. On the basis of prior experiments, mice were fed the chosen diet for 6 weeks before surgery to ensure 25D 3 sufficiency or deficiency 25 . Three days before surgery, a "rescued" group (n = 20) was created from the mice being fed a deficient diet by injecting 80 ng of 25D 3 (Enzo Life Sciences) intraperitoneally, as previously described 26 ; these mice were also switched over to a vitamin D 3 -sufficient diet (Fig. 1) . To confirm 25D 3 levels prior to rescue, prior to surgery, and in the postoperative period, retro-orbital blood draws were performed 3 days prior to surgery and on postoperative days (PODs) 0 and 14. Serum was separated via microcentrifuge. Individual samples (n = 10) from each group were pooled on PODs 23, 0, and 14 to ensure adequate content of 1,25D 3 for radioimmunoassay and 25D 3 for liquid chromatography-mass spectrometry (Heartland Assays).
Surgical Procedure
Mice were anesthetized via inhalation of isoflurane (2%). The surgical procedure was previously described 6, 27 . A skin incision was made over the right knee. The distal part of the femur was accessed through a medial parapatellar arthrotomy. The femoral medullary canal was manually reamed with a 25-gauge needle. An orthopaedic-grade stainless steel Kirschner wire (0.6 mm in diameter; DePuy Synthes) was placed in a retrograde fashion and cut with 1 mm protruding into the joint space. An inoculum of 1 · 10 3 CFUs of Xen36 in 2 mL of normal saline solution was pipetted into the joint space. The surgical site was closed with polyglycolic acid 5-0 sutures. Buprenorphine (0.1 mg/kg) was administered subcutaneously every 12 hours as an analgesic for the duration of the experiment. No antibiotics were given throughout the study period.
Quantification of Bacterial Burden Using Bioluminescence Imaging in Vivo and CFUs
Mice were anesthetized via inhalation of isoflurane (2%), and in vivo bioluminescence imaging was performed by using an in vivo imaging system (IVIS Lumina II; PerkinElmer) 28 . Images were obtained on PODs 0, 1, 3, 5, 7, 10, 14, 18, and 21. Data were presented on a color scale overlaid on a grayscale photograph of the mouse and quantified as maximum flux (photons per second per cm 2 per steradian [photons/s/cm 2 /sr]) within a circular region of interest (16,103 pixels) by using Living Image software (PerkinElmer).
To confirm that the bioluminescence signals corresponded to the bacterial burden in vivo, bacteria were quantified. On POD 21, bacteria were detached from the implant by sonication in 1 mL of 0.3% polysorbate 80 in TSB for 10 minutes followed by vortexing for 5 minutes, as previously described 6 . In addition, bacteria in the surrounding joint tissue were measured by homogenizing bone and joint tissue (Pro200H Series homogenizer; PRO Scientific). The number of bacterial CFUs that were adherent to the implant and in the joint tissue was determined by counting CFUs after overnight culture of plates and was expressed as total CFUs harvested from the implant and joint tissue.
Quantification of Neutrophil Infiltration with Fluorescence Imaging in Vivo
Fluorescence imaging in vivo was performed using the IVIS Lumina system. EGFP-expressing neutrophils within the postoperative site were visualized by using the GFP filter for excitation (445 to 490 nm) and emission (515 to 575 nm) at an exposure time of 0.5 seconds 6, 28 . The observer was not blinded to the treatment group. Data were presented on a color scale overlaid on a grayscale photograph of the mouse and quantified as maximum radiant efficiency ([photons/s]/[mW/cm 2 ]) within a circular region of interest (16,103 pixels) using Living Image software.
Quantification of Neutrophil Infiltration with
Myeloperoxidase Activity and Macrophage Recruitment with b-N-Acetylglucosaminidase Activity At the conclusion of the experiment, 3 mice per group were killed and joint-tissue specimens were homogenized. The homogenate was assayed for myeloperoxidase (MPO) activity levels, a surrogate for neutrophil infiltration, using the Myeloperoxidase Colorimetric Activity Assay Kit (SigmaAldrich) according to the manufacturer's instructions and expressed as milliunits/mL 29 . The tissue homogenate was also assayed for b-N-acetylglucosaminidase (NAG) activity levels, a surrogate for recruited tissue macrophage activity, using the b-N-Acetylglucosaminidase Assay Kit (Sigma-Aldrich) according to the manufacturer's instructions and expressed as milliunits/mL 30 .
Statistical Analysis
Each experimental group had 20 mice; in previous studies, our group determined that 20 animals per group were necessary to demonstrate significance at the p < 0.05 level 6, 29 . Data were compared using a Student t test (1 or 2-tailed where indicated). Figs. 3-A and 3-B Confirmation of bacterial burden using colony-forming unit (CFU) counts. At postoperative day 21, mice were killed and bacteria from the implant and surrounding joint tissue were processed for culture. Fig. 3 -A Box-and-whisker plots (logarithmic scale) of bacterial counts as measured by CFUs in the surrounding joint tissue of the right knee (p < 0.05 for the 25D 3 -deficient mice compared with both 25D 3 -sufficient and rescued mice). Fig. 3 -B Box-and-whisker plots (logarithmic scale) of bacterial counts as measured by CFUs adherent to the implant (p < 0.04 for the 25D 3 -deficient mice compared with both 25D 3 -sufficient and rescued mice). The horizontal line within the boxes indicates the median, the outside borders indicate the medians of the upper half and lower half of the data, and the whiskers indicate the minimum and maximum values of the data set.
SINGLE-DOSE, PREOPERATIVE V I TA M I N -D SUPPLEMENTATION D E C R E A S E S INFECTION I N A MOUSE M O D E L O F PJI
All data were expressed as the mean and the standard error of the mean (SEM). Values of p < 0.05 were considered significant.
Results

Serum Vitamin-D Metabolite Levels
T he 1,25D 3 and 25D 3 levels were higher in the mice that were fed a vitamin D 3 -sufficient diet compared with those on a vitamin D 3 -deficient diet for all 3 time points (PODs 23, 0, and 14) (Table I ). Serum 25D 3 and 1,25D 3 levels were comparable between the 25D 3 -deficient and rescued mice at POD 23; the serum 25D 3 and 1,25D 3 in the rescued group increased to levels that were comparable with those in the 25D 3 -sufficient group at PODs 0 and 14, confirming successful repletion.
Bacterial Burden Using Bioluminescence Imaging in Vivo and CFUs
The 25D 3 -sufficient, deficient, and rescued groups had similar bioluminescent signals at POD 0 (5.64 · 10 4 , 5.08 · 10 4 , and 4.94 · 10 4 photons/s/cm 2 /sr, respectively) (Fig. 2) . The bioluminescent signal for all 3 groups peaked at POD 3. From PODs 1 through 21, the 25D 3 -deficient group had a significantly higher bioluminescent signal than did the 25D 3 -sufficient group (p < 0.05 for all time points). In addition, from PODs 1 through 21, the rescued group had a bioluminescent signal that was comparable to that of the 25D 3 -sufficient group (p > 0.05 for all time points) and a significantly lower bioluminescent signal compared with the 25D 3 -deficient group (p < 0.05 for all time points).
This finding was confirmed by CFU counts from the implant and surrounding joint tissue (Fig. 3) . The average CFU count from the implant was 8.3 · 10 3 for the 25D 3 -deficient group compared with 2.4 · 10 3 for the 25D 3 -sufficient group (p < 0.05). The implant CFU count was 2.5 · 10 3 for the 25D 3 -rescued group, which was equivalent to that of the 25D 3 -sufficient group (p > 0.05) and significantly lower than that of the 25D 3 -deficient group (p < 0.04). The average CFU count from the surrounding joint tissue was 1.2 · 10 4 for the 25D 3 -deficient group compared with 5.4 · 10 3 for the sufficient group (p < 0.05). The CFU count from the surrounding joint tissue for the rescued group was 4.7 · 10 3 , which was also similar to that of the 25D 3 -sufficient group (p > 0.05) and significantly lower than that of the 25D 3 -deficient group (p < 0.05).
Neutrophil EGFP Fluorescence in Vivo
All 3 groups started with similar fluorescent signal on POD 0 (2.9 · 10 9 , 2.9 · 10 9 , and 3.1 · 10 9 [photons/s]/[mW/cm 2 ] in the 25D 3 -deficient, sufficient, and rescued groups, respectively), and the signal peaked at POD 3 for all groups (Fig. 4) . Interestingly, from PODs 1 through 21, the 25D 3 -deficient group had significantly greater fluorescent signal compared with the sufficient group (p < 0.05 for all time points). The 25D 3 -rescued group had fluorescent signal that was similar to that of the sufficient group (p > 0.05 for all time points) and significantly less fluorescent signal compared with the deficient group (p < 0.05 for all time points).
Quantification of Neutrophil Infiltration (MPO Activity) and Activated Tissue Macrophage Recruitment (NAG Activity) Mice in the 25D 3 -deficient group had significantly higher MPO activity, at 6.7 milliunits/mL (p < 0.02), than did mice in the 25D 3 -sufficient and rescued groups, which were comparable at 4.8 and 4.7 milliunits/mL, respectively (p > 0.05) (Fig. 5) . Mice in the 25D 3 -deficient group had significantly less NAG activity, at 160 milliunits/mL (p < 0.03), than did mice in the 25D 3 -sufficient and rescued groups, which were similar at 210 and 218 milliunits/mL, respectively (p > 0.05) (Fig. 5) . Although advances have been made in antimicrobial therapies and modification of health-care systems protocols, host factors have been often neglected because of the perceived difficulty in modifying them [7] [8] [9] [10] [11] [31] [32] [33] [34] . Recent work on circulating levels of 25D, the metabolite used to distinguish vitamin-D sufficiency of the host, has highlighted its importance as a host factor related to the risk of infection 13, 15 . When considering the ease with which it can be replenished, a deficient serum 25D level has the potential to be an easily modifiable risk factor in the prevention of PJI 21 . With this in mind, we sought to use our previously established in vivo mouse model of PJI to (1) evaluate the differences in bacterial burden and host immune response between 25D 3 -sufficient and deficient mice, and (2), test if this difference can be reversed with a single, preoperative dose of 25D 3 .
Discussion
In recent years, the physiological and pathophysiological roles ascribed to normal versus deficient vitamin-D balance have been broadened 35 . Recent work has demonstrated a causal link between the prohormone 25D and the normal human innate immune response [15] [16] [17] [18] [19] [20] . In pathogen-associated molecular pattern (PAMP)-activated macrophages, characterized by coupregulation of the expression of the 25D-activating enzyme gene (CYP27B1) and the vitamin-D receptor, 25D is converted to the active metabolite 1,25D intracellularly, which then binds to the vitamin-D receptor and turns on (1) antimicrobial peptide (AMP)-generating, (2) autophagy-stimulating, and (3) inflammasome-activating genes to combat infection, especially in the presence of S. aureus 15, 36 . This pathway is inoperable if extracellular levels of substrate 25D are inadequate. Clinical work by Maier et al. also demonstrated that there was a significant difference (p < 0.001) in serum 25D levels between patients who underwent primary total arthroplasty without PJI and those who developed a PJI 13 . In addition, 64% of the patients who underwent primary arthroplasty had low levels of 25D. Taken together, these recent findings highlight the potentially important role for 25D repletion in the prevention of PJI.
When comparing the 25D 3 -sufficient and deficient mice, it was clear that the bioluminescent signal was greater in the deficient mice, indicating increased bacterial burden on the implant and surrounding tissues. This was also confirmed by CFU counts on POD 21. When examining the host immune response, the 25D 3 -deficient mice had increased fluorescent signal, indicating greater neutrophil infiltration. This was confirmed by measuring MPO activity at the conclusion of the study. This is in contrast to decreased NAG activity, indicating diminished activated tissue macrophage recruitment. It is possible that inadequate host macrophage immune response leads to increased bacterial burden and this, consequently, leads to increased neutrophil infiltration in an attempt to more adequately combat the ongoing infection. Nonetheless, the data demonstrate that 25D 3 deficiency increases the severity of PJI. Moreover, the 25D 3 -deficient mice that were replenished preoperatively with 25D 3 were "rescued" from this state and had a host response to induced infection that was similar to that of the mice that were 25D 3 -sufficient. This finding opens the door to considerable further study of a low total 25D level as a risk factor that can be modified to help "prime" the immune system prior to arthroplasty.
There were several limitations to this study. One limitation was that these results were of a mouse model and thus may not be directly applicable to humans. Although this model is advantageous for the study of PJI, the size of the mice limited the blood available for testing of biomarkers and necessitated the pooling of serum for analysis. Ideally, serum values of vitamin 25D 3 and 1,25D 3 would have been measured for each mouse at a variety of time points and correlated with the level of infection for each mouse. While this would have provided a more robust analysis of the role of 25D 3 and 1,25D 3 deficiency in PJI, the aggregate data presented here establish a foundation on which more detailed work on larger animals can be conducted. In addition, an extreme state of 25D 3 deficiency was tested, which may not be as clinically pertinent a scenario in humans, who would likely present with a lesser degree of deficiency. Furthermore, observers were not blinded to the treatment group when imaging the mice, leading to the potential for detection bias. To combat this, a predetermined region of interest in size and shape was used for both bioluminescence and fluorescence imaging.
A final limitation was the use of lys-EGFP mice containing fluorescent neutrophils instead of MacGreen mice, which contain fluorescent macrophages 37 . As the macrophage is the primary cell responsible for initiating the "foreign-body reaction" to implanted hardware, it plays an important role in protecting the implant from contaminant bacteria 38 . When the 25D level in the serum of the host is too low, this results in the failure of the macrophage to mount effective autophagy (killing) of bacteria, thus blunting the innate immune response 39 .
Longitudinal visualization of the difference in macrophage response might have yielded more direct information about the effect that 25D deficiency has on the innate immune response. Nevertheless, the lys-EGFP species was previously validated in our model 28 . As such, it was thought to be more likely to produce a consistent, predictable result than a strain with a potentially different immunology. In addition, activated tissue macrophage recruitment was examined at the end of the study and demonstrated decreased activity in the 25D 3 -deficient mice. Future study using MacGreen mice may be able to more fully evaluate the difference in macrophage recruitment over the course of a PJI.
Despite these weaknesses, we believe that this study successfully provides in vivo evidence that the 25D-deficient state of the host increases bacterial burden and neutrophil infiltration in the setting of PJI. Moreover, this effect can be reversed by preoperative administration of 25D 3 . With 25D deficiency established as an important and easily modifiable risk factor in vivo, additional studies should (1) examine whether this single-dose "rescue" effect with 25D 3 administration also exists for humans, and (2) elucidate the exact mechanism behind the blunted immune response in the 25D-deficient population. In the future, a "personalized" approach to 25D 3 supplementation may be used for 25D-deficient patients prior to arthroplasty to help "prime" the immune system and prevent PJI. n
